AMGEN INC (AMGN) Stock Price & Overview
NASDAQ:AMGN • US0311621009
Current stock price
The current stock price of AMGN is 347.94 USD. Today AMGN is down by -1.51%. In the past month the price decreased by -5.35%. In the past year, price increased by 18.19%.
AMGN Key Statistics
- Market Cap
- 187.564B
- P/E
- 15.92
- Fwd P/E
- 15.24
- EPS (TTM)
- 21.85
- Dividend Yield
- 2.85%
AMGN Stock Performance
AMGN Stock Chart
AMGN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AMGN. When comparing the yearly performance of all stocks, AMGN turns out to be only a medium performer in the overall market: it outperformed 62.05% of all stocks.
AMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMGN. AMGN scores excellent on profitability, but there are concerns on its financial health.
AMGN Earnings
On February 3, 2026 AMGN reported an EPS of 5.29 and a revenue of 9.87B. The company beat EPS expectations (9.56% surprise) and beat revenue expectations (2.11% surprise).
AMGN Forecast & Estimates
42 analysts have analysed AMGN and the average price target is 360.65 USD. This implies a price increase of 3.65% is expected in the next year compared to the current price of 347.94.
For the next year, analysts expect an EPS growth of 4.46% and a revenue growth 4.11% for AMGN
AMGN Groups
Sector & Classification
AMGN Financial Highlights
Over the last trailing twelve months AMGN reported a non-GAAP Earnings per Share(EPS) of 21.85. The EPS increased by 10.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.98% | ||
| ROA | 8.51% | ||
| ROE | 89.06% | ||
| Debt/Equity | 5.78 |
AMGN Ownership
AMGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AMGN
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
IPO: 1983-06-17
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320 US
CEO: Robert A. Bradway
Employees: 31500
Phone: 18009279800
AMGEN INC / AMGN FAQ
Can you describe the business of AMGEN INC?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 31,500 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
What is the stock price of AMGEN INC today?
The current stock price of AMGN is 347.94 USD. The price decreased by -1.51% in the last trading session.
Does AMGEN INC pay dividends?
AMGEN INC (AMGN) has a dividend yield of 2.85%. The yearly dividend amount is currently 9.01.
What is the ChartMill rating of AMGEN INC stock?
AMGN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting AMGN stock to perform?
42 analysts have analysed AMGN and the average price target is 360.65 USD. This implies a price increase of 3.65% is expected in the next year compared to the current price of 347.94.
Can you provide the growth outlook for AMGEN INC?
The Revenue of AMGEN INC (AMGN) is expected to grow by 4.11% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for AMGEN INC?
AMGEN INC (AMGN) has a market capitalization of 187.56B USD. This makes AMGN a Large Cap stock.